A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
Clinical trial NCT04813107 · UNKNOWN
Trial details
- NCT number
- NCT04813107
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-28
- Primary completion
- 2023-11-01
- Enrollment
- 79
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.